Regulatory Milestones

Celgene Corp. (NASDAQ:CELG) was off $1.21 to $51.55 last week after the U.K.'s NICE issued a preliminary appraisal recommending thalidomide in combination with an alkylating agent and a corticosteroid for first-line treatment of multiple myeloma (MM) in patients for whom high-dose chemotherapy with stem cell transplantation is inappropriate (see Online Links, A17).

Photocure ASA (OSE:PHO) gained NOK6.1 (16%) to NOK44 last Monday when investors were able to react to the prior Saturday's news that FDA approved an NDA for Cysview hexaminolevulinate to detect non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer. The aminolevulinic acid (ALA) derivative photosensitizer is marketed in Europe and Korea as Hexvix. Photocure was up NOK2.40 to NOK40.30 for the week...